Table 9 Results of subgroup analysis and interaction analysis

Age (years)

0.07

0.30

  < 60 (years)

177

0.81 (0.54, 1.20)

-0.60 (-2.01, 0.81)

  ≥ 60 (years)

577

0.53 (0.37, 0.75)

-1.41 (-2.19, -0.63)

Gender

0.21

0.11

 Male

522

0.64 (0.47, 0.89)

-0.97 (-1.80, -0.13)

 Female

232

0.41 (0.22, 0.76)

-2.15 (-3.37, -0.94)

Urinary occult blood

0.64

 < 0.05

 No

511

0.53 (0.34, 0.80)

-0.84 (-1.72, 0.04)

 Yes

243

0.60 (0.40, 0.91)

-2.37 (-3.39, -1.36)

BMI (kg/m2)

0.10

0.96

  < 23.5

381

0.45 (0.30, 0.68)

-1.61 (-2.50, -0.72)

  ≥ 23.5

373

0.72 (0.47, 1.10)

-1.58 (-2.57, -0.59)

UPCR (g/gCr)

0.97

0.17

  < 3.5

595

0.59 (0.38, 0.91)

-1.47 (-2.29, -0.64)

  ≥ 3.5

159

0.58 (0.41, 0.84)

-2.43 (-3.58, -1.27)

Etiology of CKD

 < 0.05

0.13

 Diabetic nephropathy

182

0.86 (0.56, 1.32)

-1.79 (-3.17, -0.40)

 Nephrosclerosis,

305

0.23 (0.12, 0.44)

-1.69 (-2.82, -0.57)

 Glomerulonephritis

147

0.52 (0.21, 1.25)

-1.49 (-3.13, 0.15)

 Other

120

1.80 (0.69, 4.68)

0.29 (-1.22, 1.80)

Use of RAAS inhibitor

0.63

0.22

 No

250

0.71 (0.39, 1.31)

-1.92 (-3.02, -0.82)

 Yes

504

0.61 (0.43, 0.85)

-1.11 (-1.94, -0.27)

Hypertension

0.42

0.85

 No

71

0.28 (0.04, 1.97)

-1.56 (-3.82, 0.70)

 Yes

683

0.61 (0.45, 0.82)

-1.33 (-2.07, -0.59)

History of CVD

0.42

0.94

 No

561

0.68 (0.46, 1.00)

-1.42 (-2.24, -0.60)

 Yes

193

0.54 (0.36, 0.81)

-1.47 (-2.50, -0.45)

Diabetes

0.09

0.13

 No

477

0.49 (0.33, 0.72)

-1.72 (-2.56, -0.89)

 Yes

277

0.73 (0.51, 1.06)

-0.68 (-1.82, 0.48)

Use of CCB

0.64

0.26

 No

373

0.65 (0.45, 0.93)

-1.81 (-2.74, -0.89)

 Yes

381

0.58 (0.41, 0.84)

-1.09 (-2.05, -0.14)

Use of diuretics

0.96

0.24

 No

515

0.59 (0.40, 0.87)

-1.11 (-1.97, -0.26)

 Ye

239

0.60 (0.41, 0.89)

-1.91 (-3.00, -0.83)

CKD stage

0.63

0.51

 2

62

0.44 (0.12, 1.62)

-1.04 (-3.65, 1.56)

 3

327

0.56 (0.36, 0.87)

-0.61 (-1.77, 0.56)

 4

250

0.69 (0.48, 1.01)

-1.82 (-3.00, -0.65)

 5

115

0.80 (0.47, 1.35)

-1.30 (-3.20, 0.59)